Waker Biology
Minhang
About Waker Biology
Waker Biology is a platform developer for evaluating the safety of gene therapy. The business's primary research and development efforts are directed toward high-precision crispr/cas 9 quantitative off-target analysis, vector copy number, vector quality control, immune repertoire analysis, and effective sgRNA screening. It offers clients a full range of personalized services, from accepting samples to submitting reports.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $14.1M
- Funding stage: Early Stage Venture
- Last round: Series A (Nov 2025)
- Website: wakerbio.com
- Phone: 021-33975037
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical
Canonical: https://fsome.com/organization/waker-biology-55355 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.